Another checkpoint inhibitor, pembrolizumab (Keytruda®) that targets the PD‐1/PD‐L1 pathway, was approved for a subset of patients with advanced CRC having MSI‐H, dMMR, or high tumor mutational burden [265]. Here, CD274 is linked to neoplasm.